AU1333797A - Method for obtaining retroviral vector supernatant having high transduction efficiency - Google Patents

Method for obtaining retroviral vector supernatant having high transduction efficiency

Info

Publication number
AU1333797A
AU1333797A AU13337/97A AU1333797A AU1333797A AU 1333797 A AU1333797 A AU 1333797A AU 13337/97 A AU13337/97 A AU 13337/97A AU 1333797 A AU1333797 A AU 1333797A AU 1333797 A AU1333797 A AU 1333797A
Authority
AU
Australia
Prior art keywords
cells
supernatant
vector
propak
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13337/97A
Other languages
English (en)
Inventor
Ernst Bohnlein
Jonathan S. Dando
Sean P. Forestell
Richard J. Rigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systemix Inc
Original Assignee
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/572,959 external-priority patent/US5910434A/en
Application filed by Systemix Inc filed Critical Systemix Inc
Publication of AU1333797A publication Critical patent/AU1333797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU13337/97A 1995-12-15 1996-12-13 Method for obtaining retroviral vector supernatant having high transduction efficiency Abandoned AU1333797A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57294395A 1995-12-15 1995-12-15
US572959 1995-12-15
US572943 1995-12-15
US08/572,959 US5910434A (en) 1995-12-15 1995-12-15 Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
PCT/US1996/019904 WO1997021824A2 (en) 1995-12-15 1996-12-13 Method for obtaining retroviral vector supernatant having high transduction efficiency

Publications (1)

Publication Number Publication Date
AU1333797A true AU1333797A (en) 1997-07-03

Family

ID=27075989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13337/97A Abandoned AU1333797A (en) 1995-12-15 1996-12-13 Method for obtaining retroviral vector supernatant having high transduction efficiency

Country Status (5)

Country Link
EP (1) EP0871753A2 (ja)
JP (1) JP2000501614A (ja)
AU (1) AU1333797A (ja)
CA (1) CA2238434A1 (ja)
WO (1) WO1997021824A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
TR201900968T4 (tr) 2004-09-24 2019-02-21 Mesoblast Inc Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
EP1869165B1 (en) 2005-04-12 2015-10-21 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US8609411B2 (en) 2007-05-04 2013-12-17 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
KR20150021587A (ko) 2007-08-06 2015-03-02 메소블라스트, 아이엔씨. 생체 내에서 결합 조직을 생성, 복구 및/또는 유지하는 방법
SG10201503304RA (en) * 2007-12-27 2015-06-29 Baxter Int Cell culture processes
SG10201601279SA (en) 2008-08-18 2016-03-30 Mesoblast Inc Monoclonal Antibody STRO-4
WO2014022373A1 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
CA2880811C (en) 2012-08-01 2021-12-07 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
EP3878452B1 (en) 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
JP6730193B2 (ja) * 2014-04-25 2020-07-29 ジェネトン 高ビリルビン血症の処置
DK3215601T3 (da) 2014-11-05 2020-06-15 Juno Therapeutics Inc Fremgangsmåder til transduktion og celleforarbejdning
WO2018080990A1 (en) 2016-10-24 2018-05-03 United Therapeutics Corporation Enhancement of msc immunomodulatory properties by treprostinil
CA3075679A1 (en) 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
WO2024075819A1 (ja) * 2022-10-07 2024-04-11 Ａｇｃ株式会社 細胞を用いたウイルスベクターの生産方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3069189A (en) * 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
AU6248994A (en) * 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
EP0769968B1 (en) * 1994-08-17 2005-01-26 Genetic Therapy, Inc. Retroviral vectors produced by producer cell lines resistant to lysis by human serum

Also Published As

Publication number Publication date
EP0871753A2 (en) 1998-10-21
WO1997021824A2 (en) 1997-06-19
WO1997021824A3 (en) 1997-09-04
CA2238434A1 (en) 1997-06-19
JP2000501614A (ja) 2000-02-15

Similar Documents

Publication Publication Date Title
CA2238436C (en) Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1997021825A9 (en) Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
RIGG et al. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety
AU1333797A (en) Method for obtaining retroviral vector supernatant having high transduction efficiency
Persons et al. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene
JP5760023B2 (ja) 安全性の改善された発現ベクター
AU6248994A (en) Production of high titer helper-free retroviruses by transient transfection
Forestell et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer
Uckert et al. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype
US5710037A (en) Retroviral vector particles
WO1995034639A9 (en) Novel retroviral envelope and ltr and retroviral vector particles including such envelope and/or ltr
WO1998013511A1 (en) Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
WO1998013511A9 (en) Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
EP0859856A2 (en) Stable packaging cell line producing pseudotyped retroviruses
US5837536A (en) Expression of human multidrug resistance genes and improved selection of cells transduced with such genes
EP0821740A1 (en) High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
US5766945A (en) 10A1 Retroviral packaging cells and uses thereof
KR100359542B1 (ko) 레트로바이러스 벡터를 위한 부유성 패키징 세포주
IL116216A (en) Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
Bauer et al. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line
US7015035B2 (en) RD114-based retroviral packaging cell line and related compositions and methods
US20020164800A1 (en) Retroviral vector
Anson Retroviral-mediated gene transduction
Kewney Evaluation of safety and methods for production of retroviral vectors for use in gene therapy
WO1998050538A1 (en) Mus dunni endogenous retroviral packaging cell lines

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted